Journal of Medical Economics
Volume 24, 2021 - Issue 1
Neurology
In Reply to Xue W, Ribalov R, Zhou Z-Y, et al. Re: Ganz ML, Chavan A, Dhanda R, et al. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. J Med Econ. 2021;24(1):103–113
Michael Serbina Neurocrine Biosciences Inc., San Diego, CA, USA
https://orcid.org/0000-0001-6876-7150
https://orcid.org/0000-0001-6876-7150, Charles Yonana Neurocrine Biosciences Inc., San Diego, CA, USAhttps://orcid.org/0000-0002-6374-327X
https://orcid.org/0000-0002-6374-327X & Michael L. Ganzb Real-world Evidence, Evidera, Waltham, MA, USACorrespondence[email protected]
https://orcid.org/0000-0002-9702-2999
https://orcid.org/0000-0002-9702-2999